Modulation of Mucosal and Systemic Immunity by Enteric Administration of Nonreplicating Herpes Simplex Virus Expressing Cytokines  by Kuklin, Nelly A. et al.
Modulation of Mucosal and Systemic Immunity by Enteric Administration
of Nonreplicating Herpes Simplex Virus Expressing Cytokines
Nelly A. Kuklin, Massoud Daheshia, Peggy C. Marconi, David M. Krisky, Richard J. D. Rouse, Joseph C. Glorioso,
Elanchethiyan Manican, and Barry T. Rouse
Department of Microbiology, University of Tennessee, Knoxville, Tennessee 37996-0845; and Department of Biochemistry,
Molecular Biology, University of Pittsburgh, Pittsburgh, Pennsylvania 15260
Received August 9, 1997; returned to author for revision October 9, 1997; accepted October 31, 1997
In this report the ability of enteric immunization with recombinant replication deficient (ICP42/2) HSV expressing IFNg to
generate protection and modulate mucosal and systemic immunity was evaluated. ICP42/2HSV, ICP42/2HSV expressing
IL4, live replicating, and uv HSV were used as controls. Following enteric administration of live HSV, a Th1 cytokine response
was induced in the spleen, while both Th1 and notable Th2 cytokine production were detected at mucosal sites. Modulation
of mucosal and systemic immune response was achieved when nonreplicating recombinant HSV viruses expressing
cytokines were used. Compared to the control replication defective viruses, decreased frequency of Th2 cytokine producing
cells in Peyer’s patches was observed following enteric administration of nonreplicating HSV expressing IFNg. When IFNg
expressing virus was given enterically, modulation was observed at the systemic level, measured by ELISPOT for cytokine
producing cells, ELISA from the in vitro restimulated splenic cell cultures, and by the increase of the IgG2a/IgG1 ratio in the
serum. This report provides evidence that replication defective viruses expressing cytokine genes in contrast to uv HSV, are
immunogenic when administered enterically and can generate significant immunomodulatory effects at the mucosal and
systemic levels. © 1998 Academic Press
INTRODUCTION
Herpes simplex virus (HSV) remains a conspicuous
cause of human disease so far uncontrolled by an ac-
ceptable vaccine. Many candidate vaccines have been
developed but none have passed the scrutiny of inde-
pendent evaluation in the United States. Vaccines should
be effective, at least when used prophylactically, since
the two subtypes are antigenically stable and vaccines
against similar alphaherpesviruses in animals appear
satisfactory (Mester et al., 1996). Herpesvirus vaccinolo-
gists have focused on inducing systemic immunity and
have largely ignored the issue of mucosal defense. The
virus, particularly HSV-2, enters the body mainly through
mucosal surfaces and it remains possible that solid
immunity at such sites could provide an obstacle to viral
invasion. Since the pioneering observations in the late
1960s (Tomasi and Bienenstock, 1968), it became evident
that mechanisms of immunity which protect mucosal
sites may differ from those operative at systemic loca-
tions. Moreover, a common mucosal immune system
exists which may respond to different vaccination strat-
egies than those found adequate for systemic use (Mc-
Dermott and Bienenstock, 1979).
Mucosal immunity to HSV has received some study in
mouse models (Mester et al., 1996). Genital immunity has
been the focus since HSV is an important sexually trans-
mitted disease in humans (Corey and Spear, 1986). Vag-
inal immunity can be induced following either vaginal or
nasal exposure to attenuated HSV (McDermott et al.,
1984; Milligan and Bernstein, 1995a), but systemic immu-
nization usually fails to induce similar mucosal re-
sponses (McDermott et al., 1990). In addition, the vaginal
route itself, in lacking a major accumulation of mucosal
associated lymphoid tissue (MALT) is an inferior means
of inducing mucosal immunity compared to other muco-
sal routes (Parr and Parr, 1994). For example, recombi-
nant adenovirus expressing the gB protein of HSV given
intranasally induced a good vaginal IgA and T cell re-
sponse (Gallichan and Rosenthal, 1995), but given vagi-
nally provided no vaginal IgA. Interestingly, weak sys-
temic immune responses occurred, indicating that the
vector likely replicated in vaginal tissue (Gallichan and
Rosenthal, 1995). The oral route provides by far the most
convenient means of inducing mucosal immunity. Two
reports indicate that orally administered HSV induces
immunity (Irie et al., 1992, 1993). Such ‘‘intragastric’’ ad-
ministration of replication competent virus induced sys-
temic immunity as well as mucosal responses measured
by the presence of antibody secreting cells in the Peyer’s
patches of the gut (Irie et al., 1993). Whether or not
vaginal mucosal immunity had additionally occurred was
not mentioned.
In the present report, we have evaluated enteric im-
munization as a means of inducing various aspects of
immunity at systemic and the distal vaginal mucosal
sites. The immunogenicity of enterically administered,
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replication incompetent HSV viruses was also mea-
sured. Several recent publications describe the capacity
of replication incompetent viruses to protect against HSV
infection (Nguyen et al., 1992; Morrison and Knipe, 1994;
Farrell et al., 1994; Decosta et al., 1997). All of these
studies have used systemic routes of immunization. One
recent report has explored mucosal administration of
replication incompetent viruses in guinea pig (McLean et
al., 1996). In addition, Milligan and Bernstein (1995b)
showed that following intravaginal inoculation of replica-
tion competent tk-HSV infection, the urogenital cellular
response induced was predominantly CD41 Th1. Fur-
thermore, it was shown that protection against zosteri-
form HSV challenge is a function of CD4 Th1 cells (Man-
ickan et al., 1995). These observations indicate that
future vaccines should be designed to enhance the Th1
cellular response. In the present study replication incom-
petent rHSV expressing IFNg was used to enhance the
Th1 pattern of immune response at inductive mucosal
and systemic locations. Since such viruses can readily
be engineered to express recombinant cytokine proteins,
the approach might provide a means of shifting the
nature of T cell responses at mucosal and/or systemic
sites.
Our results show that enteric immunization with infec-
tious HSV induces systemic T cell responses dominated
by the Th1 pattern. However, mucosal responses include
a major Th2 component. Immunity, both systemic and
mucosal, was also induced by replication incompetent
virus and the additional expression of IFNg provided
change in the nature of the immune response detected
at systemic and mucosal sites. Our results indicate the
value of enteric immunization not only as a means of
achieving protective immunity but also as a method of
maneuvering the nature of immunity at mucosal sites.
RESULTS
Enteric immunization generates systemic and distal
mucosal immunity
Following enteric immunization with infectious virus,
animals developed HSV specific humoral and cellular
immune responses at both systemic and mucosal sites
(Figs. 1–3). Serum antibody production, measured by
ELISA, revealed a reactivity profile similar to that previ-
ously noted with i/m immunization (Fig. 1) and reflected
a Th1 dominated pattern. Thus IgG2a antibodies predom-
inated over IgG1 (Fig. 1). At mucosal sites, HSV specific
IgA antibodies were readily detectable following enteric
immunization, but were barely observed after im immu-
nization (Fig. 1A). Additionally, far more HSV specific IgA
producing cells were evident in the distal mucosal vag-
inal DLN following enteric immunization than occurred
after im immunization (Fig. 1B). These ELISPOT mea-
surements were made 4 days following intravaginal HSV
infection; otherwise too few cells were available for anal-
ysis.
T cell immune responses following enteric immuniza-
tion were measured by the ELISPOT technique to enu-
merate cells in the spleen, mesenteric LN, and, in some
experiments, Peyer’s patches. Spleens and mesenteric
LN were removed at days 0, 3, 5, and 11 following enteric
live HSV administration and without further restimulation
were subjected to ELISPOT cytokine analysis. The re-
sults expressed in Fig. 2 show that the response in the
spleen was dominated by IFNg producing cells (Th1
FIG. 1. Induction of systemic and mucosal antibodies following enteric or intramuscular immunization with HSV. BALB/c mice 4 to 5 weeks old were
deprived of food for 2 h and subsequently were given HBSS and sodium bicarbonate (4:1) to neutralize the stomach acidity. Thirty minutes later 1 3
106 PFU of live or UV inactivated HSV KOS (titrated before inactivation) was administered enterically with the help of a gavage needle. The
immunization was repeated two times. Fifteen days following the last immunization serum, fecal, and vaginal samples were collected and the antibody
levels were measured by ELISA (A). At day 20 the mice were given DP and 5 days later challenged intravaginally as described under Material and
Methods. Vaginal draining LN were removed 4 days following challenge and the frequency of total or HSV specific IgA spot forming cells (SFC) was
determined by ELISPOT (B).
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pattern), whereas in the mesenteric LN, IL-5, IL-4, as well
as IFNg producing cells were observed (Both Th1 and
Th2 pattern). ELISPOT analysis was also performed on
spleen and Peyer’s patch cells following additional in
vitro antigen stimulation. Once again, IFNg producing
cells dominated splenic responses but Peyer’s patches
contained spot forming cells for IL-5 and IFNg (Fig. 3).
Cytokine producing cells were also measured in splenic
and enteric lymphoid (pp) tissue following im adminis-
tration of HSV. As with enteric immunization, splenic SFC
were predominantly IFNg, but, responses in the Peyer’s
patches were marginal (Fig. 3).
Enteric immunization with replication incompetent
virus generates immunity
Although enteric immunization with infectious virus led
to excellent immune responses at both systemic and
mucosal sites, inactivated virus given by the same route
usually failed to induce detectable immunity (Fig. 1; Table
1). However, immunization with recombinant viruses
lacking an immediate–early gene and thereby unable to
replicate did induce immunity, although responses were
quantitatively inferior both systemically and mucosally
than those that occurred following similar immunization
with replication competent virus (Table 1). Immune re-
sponses were also measured against two recombinant
HSV engineered to express either IFNg or IL-4. It is
evident that following enteric immunization, total serum
HSV specific IgG levels were equivalent, yet the nature of
the IgG subset responses differed. Thus, responses to
the IFN-g recombinant virus were more Th-1-like (higher
IgG2a:IgG1 ratio) than those that occurred in animals
enterically immunized with the IL-4 recombinant (Table
1). Both cytokine recombinants induced mucosal IgA in
FIG. 2. Frequency of cytokine producing cells from MLN and spleen induced by enteric HSV immunization. BALB/c mice 3 to 4 weeks old were
deprived of food for 2 h and subsequently were given enterically 200 ml of sodium bicarbonate in HBSS (4:1) to neutralize the stomach acidity. Thirty
minutes later the mice were given enterically 1 3 106 PFU of HSV-1 KOS. Four mice were sacrificed at days 0, 3, 5, 7, and 11 following the enteric
HSV administration. Spleen and MLN were removed and the frequency of cytokine producing cells was determined using ELISPOT analyses. Data
from two independent experiments are presented. The top two figures represent MLN cytokine SFC, and the bottom two figures represent splenic
cytokine responses.
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feces as well as vaginal washes, and antibody levels
were approximately equal (Table 1).
T cell responses to enteric immunization with replica-
tion incompetent HSV measured in spleen and Peyer’s
patches also reflected an influence of expressing either
IFNg or IL-4 in the recombinant virus. In the spleen
responses to all three recombinant viruses (IFNg, IL-4,
and control) reflected a Th1 dominated response pattern,
with the IFNg recombinant providing the best response
(Fig. 4A). Cytokine levels from the supernatant of spleno-
cytes following in vitro restimulation revealed enhanced
IFNg production when d120 IFNg virus was given enteri-
cally compared to d120 or d120IL4 producing virus (Table
2). In Peyer’s patches, the control and IL-4 expressing
virus induced responses which were mainly Th2 type.
Interestingly the IFNg recombinant generated barely de-
tectable Peyer’s patch responses, possibly reflecting an
inhibitory effect of IFNg expression on the Th2 response
(Fig. 4B).
Resistance to challenge
To measure the immune status of enteric vaccines,
groups of animals immunized with replicating virus or
FIG. 3. BALB/c mice, six per group, were immunized intramuscularly (im) or enterically (en) with 1 3 106 PFU of live HSV KOS. Seven days following
immunization, splenocytes and (A) and Peyer’s patch cells (B) from immune animals were in vitro restimulated with HSV infected or naive enriched
populations of DC. The frequency of cytokine producing cells was determined using ELISPOT assay. Background spot forming cells numbers
(effectors stimulated with naive DC) were subtracted from those obtained from effector cells stimulated with HSV pulsed DC. Standard deviation for
the spleen SFC is based on the values of three groups of two mice. In the case of PP cells were pooled from six mice and the standard deviation
is based on the three replicates per group.
TABLE 1
Mucosal and Systemic Humoral Responses Following Enteric Immunization with Nonreplicating (ICP42/2)
Recombinant HSV Viruses Expressing Cytokine Genes for IFNg or IL4
Immunization
agent IgG (ng/ml) IgG2a (ng/ml) IgG1 (ng/ml) IgG2a/IgG1 Fecal IgA Vaginal IgA
d120 IFNg 3364 6 2242 592 6 545a 57 6 47 10.3 92 6 66 32 6 20
d120 IL4 3245 6 2821 294 6 317b 67 6 34 4.3 47 6 33 60 6 10
d120 1755 6 995 179 6 70c 35 6 30 5.1 38 6 6.5 52 6 15
UV HSV ,20 0 0 — 15 6 7 0
Live HSV 12091 6 973 2541 6 1025 284 6 20 9 997 197 6 40
PBS ,5 0 0 — ,6 0
Note. BALB/c mice 3–4 weeks old were deprived of food for 2 h and were given enterically 200 ml of HBSS and sodium bicarbonate (4:1) to
neutralize the gastric acidity. Subsequently each mouse was enterically immunized with 1 3 107 PFU of d120 IFNg, d120 IL4, d120, 1 3 106 live HSV,
1 3 107 PFU of UV HSV (titrated prior to inactivation), or PBS. Immunization was repeated two times at 10-day intervals. Samples were collected 20
days following the last boost and were tested for presence of anti HSV antibodies by ELISA. Each group consists of five to seven animals and the
SD is based on individual samples tested. Groups a and b; a and c; and b and c have P . 0.05. 1d120 ICP42/2, 2d120 IFNg ICP42/2 v. HSV
expressing IFNg, 3d120 IL4 ICP42/2 v. HSV expressing IL4.
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recombinant nonreplicating virus were challenged either
systemically or vaginally with a lethal dose of HSV. The
zosteriform model, used extensively in our laboratory
(Manickan et al., 1995), was used to assess systemic
immunity and a lethal dose challenge infection was
used. For mucosal challenge, animals were first synchro-
nized into diestrus hormonal stage to standardize their
susceptibility to HSV as described previously by Parry et
al. (1994). The results of several experiments are cumu-
lated in Table 3. It is event that enteric immunization with
replicating virus produced solid protection to both sys-
temic and mucosal challenge. Indeed such mice can
also resist challenge at 100-fold higher does (data not
shown). All animals enterically immunized with UV-inac-
tivated virus remained susceptible to both systemic and
mucosal challenge. The pattern of events in animals
enterically immunized with recombinant viruses was
somewhat irregular. However, the majority of animals
resisted mucosal challenge and in the small experiment
involving systemic challenge, all resisted systemic chal-
lenge. Although a higher percentage of animals immu-
nized with the IFNg expressing virus survived mucosal
challenge than those immunized with the IL-4 virus, the
differences were not statistically significant.
DISCUSSION
In this report we show that administration of HSV to
the enteric tract in a way which avoids viral damage by
stomach acidity is an effective means of inducing muco-
sal as well as systemic immunity. Mucosal immunity,
both humoral and cellular, was evident not only in the
FIG. 4. Antigen driven cytokine response measured by ELISPOT. (A) Spleen and (B) Peyer’s patches spot forming cells (SFC) from enterically immunized mice
with replication deficient rHSV expressing cytokines. BALB/c mice were deprived of food for 2 h. Subsequently the mice were given enterically isotonic solution
containing sodium bicarbonate in HBSS (4:1) to neutralize the gastric acidity. Thirty minutes later the mice were given enterically 1 3 107 PFU of replication
incompetent HSV or replication incompetent HSV expressing cytokines. Seven days following virus administration the mice were sacrificed and spleen and PP were
removed. These cells were in vitro restimulated with naive or UV HSV pulsed DC as described under Materials and Methods. Splenic responses were determined
from cells of two spleens pooled together. PP cells were pooled from six mice. Statistics: In A, * and ***P 5 0.012, * and **P 5 0.02, ** and ***P 5 0.2. In B,
IFNg, 1 and 111P 5 0.01, 1 and 11P 5 0.03, 11 and 111P 5 0.01; IL4, 1 and 111P 5 0.2, 1 and 11P 6 0.01, 11 and 111P 5 0.03; IL5, 1 and
111P 5 0.01, 1 and 11P 5 0.01, 11 and 111P 5 0.27.
TABLE 2
Cytokine Production Profile of Replication Defective Recombinant HSV-Primed Splenocytes upon in Vitro Restimulation with HSV
Enteric immunization
IFNg (pg/ml) IL5 (pg/ml) IL10 (pg/ml)
HSV stim. Con A HSV stim. Con A HSV stim. Con A
d120 IFNg 6,700 13,700 80 3900 0 8,000
d120 IL4 800 12,400 400 6200 700 4,200
d120 1,700 12,050 500 6400 0 10,000
Live HSV 33,000 22,000 1200 3500 2200 2,000
Note. BALB/c mice were immunized as described under Material and Methods. Immune splenocytes obtained 20 days following last immunization
were in vitro restimulated with 2 m.o.i. of uv-inactivated HSV-1 (KOS strain) or Con A (5 mg/5 3 106 cells/ml) and incubated for 72 h at 37°C. Cell
supernatants were collected and tested for the level of IFNg, IL5, and IL10 cytokines by ELISA.
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gut, confirming a previous report (Irie et al., 1993), but
also at the distal vaginal mucosal location, a common
site of entry and disease expression by HSV. Intramus-
cular exposure to HSV, in contrast, was an ineffective
means of inducing mucosal immunity particularly in the
gut. Whereas enteric immunization with infectious HSV
proved highly immunogenic and effectively protected
mice against either systemic or mucosal challenge, sim-
ilar immunization with UV inactivated virus failed to in-
duce immunity. Of interest, however, actual viral replica-
tion appeared unnecessary for immunogenicity since
enteric immunization with a mutant virus lacking the
essential immediate–early protein ICP4, and so unable
to replicate (Rice and Knipe, 1990), induced both sys-
temic and mucosal immunity. Responses were quantita-
tively less than was evident after immunization with rep-
licating virus, but they were nonetheless sufficient to
confer protection against either systemic or mucosal
challenge.
Since the mutant HSV viruses have been engineered
to express a wide range and ever increasing number of
recombinant genes, including many potentially able to
maneuver the nature of the immune response, immuni-
zation with such recombinants represents a potential
means of achieving designer immunity. Our data pro-
vided modest support for this calculation. Thus a com-
parison of the IgG isotype pattern of serum antibody
responses to recombinant viruses expressing IFNg on
IL-4 revealed IgG2a:IgG1 ratios that emphasized the Th1
pattern following immunization with the IFNg recombi-
nant. Enhancement of the frequency of IFNg producing
spleen cells following in vitro restimulation was also
observed when IFNg producing virus was used. Addi-
tionally splenocytes from animals given IFNg producing
HSV generated higher IFNg and lower IL5 and IL10
cytokines upon stimulation in vitro with HSV compared to
mice immunized with IL4 producing virus or control non-
replicating HSV. The cytokine effect was also evident
from measures of T cell immunity at least in the gut itself.
Here it was observed that responses with both the par-
ent mutant and IL-4 expressing viruses were positive and
mainly Th2 in nature but only minimal responses oc-
curred upon immunization with the IFNg expressing vi-
rus. Since the same IFNg expressing virus did generate
detectable T cell responses in the spleen, as well as
serum antibody, the failed Peyer’s patch Th2 reactions
may indicate a local inhibitory effect of IFNg expression.
Although our using recombinant viruses given enteri-
cally represents a novel approach, so far its strongest
message is that the strategy works in principle but de-
signer immunity with definitive in vivo consequences has
yet to be achieved. Thus, the aim remains to induce
qualitative differences in the nature of immune response
induction at the distal vaginal mucosal site and deter-
mine if such a response correlates with protective im-
munity. The hypothesis is that protection against both
systemic and mucosal (vaginal) challenge is primarily
dependent on CD4 Th1 mediated immunity (Manickan et
al., 1995; Milligan and Bernstein, 1995b). However, in our
study although we succeeded in part to change the
immune response more toward Th1 using IFNg produc-
ing rHSV, the Th2 enhancement by IL4 expressing rHSV
achieved was less pronounced and only marginal differ-
ences were evident in terms of resistance to HSV chal-
lenge. Before we reject the guiding hypothesis regarding
resistance mechanisms, it may be necessary to design
recombinant viruses which express greater amounts of
regulatory cytokines or perhaps a different assemblage
of multiple immunomodulatory molecules to provide a
more prominent Th2 response. Thus we are currently
developing and testing additional constructs for their
value to maneuver the nature of mucosal and systemic
TABLE 3
Protection against HSV Challenge
Immunization
Intravaginal challenge
Zosteriform challenge
(protected/No. mice used)Protected/No. mice used
Disease score
Day 5 Day 6 Log of virus at day 6 postchallenge
d120 IFNg 15/19 0.7 6 1.2i 1.3 6 2.2a 1.9 6 0.61 6/6
d120 IL4 13/18 1.2 6 1.0ii 2.0 6 2.0b 2.2 6 1.02 5/5
d120 10/19 1.3 6 1.2iii 2.0 6 2.1c 2.0 6 0.83 5/6
UV HSV 0/4 3.0 6 1.4 3.9 6 1.0 3.9 6 0.3 0/5
Live HSV 7/7 0 0 0 6/6
PBS 2/16 3.6 6 1.7iv 4.1 6 1.6d 4.1 6 0.24 0/5
Note. BALB/c mice were given enterically 1 3 107 PFU of d120, d120 IFNg, d120 IL4, or 1 3 106 PFU of live HSV KOS or 1 3 107 PFU of UV HSV
(titrated prior to inactivation) PBS. The immunization was repeated two times at 10-day intervals. Twenty days following the last immunization, the mice
were challenged with 5 3 105 PFU of HSV-1 McKrae. (The data are cumulated from three independent experiments.) Some of the mice were
challenged intracutaneously with 1 3 104 of HSV-1 17. Groups i and ii, i and iii, and ii and iii have P . 0.05. Groups a and b, a and c, and b and c
have P . 0.05. Groups i, ii, and iii compared to iv have P , 0.01. Groups a, b, and c compared to d have P , 0.01. Groups 1, 2, and 3 compared to
4 have P , 0.01.
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reactivity. Our results could be relevant to the important
issue of HSV vaccines in humans. Accordingly, oral im-
munization with acceptable mutants might represent a
valuable means of managing infection by this important
venereal agent.
MATERIALS AND METHODS
Mice
Female BALB/c mice (H2-d), 3 to 4 weeks old (Harlan
Sprague-Dawley, Indianapolis, IN), were used. During
the experimental procedures, the investigators adhered
to guidelines proposed by the committee on the care of
Laboratory of the Animal Resources, Commission of Life
Sciences, National Research Council. The animal facili-
ties of The University of Tennessee are fully accredited
by the American Association for Accreditation of Labo-
ratory Animal Care.
Virus
HSV-1 (KOS) or HSV-1 McKrae were grown on vero cell
monolayers (ATCCCCL81). Mutant ICP42/2 (d120) HSV,
ICP42/2 HSV expressing IFNg (d120 IFNg), or ICP42/2
HSV expressing IL4 (d120 IL4) were grown as described
previously (Huard et al., 1995; Shepard and DeLuca,
1991) on ICP4 supplementing vero cells (E5) kindly pro-
vided by Dr. DeLuca (University of Pittsburgh). The vi-
ruses were stored in aliquots at 280°C until used. The
titers were expressed as plaque forming units (PFU)/ml
as described by others (Manickan et al., 1995).
Immunization of mice
Prior to immunization, mice were deprived of food for
2 hours. Isotonic solution (200 ml per mouse) containing
13 Hank’s balanced salt solution (HBSS) mixed with 7.5%
sodium bicarbonate (4:1) was then administered intra-
gastrically to neutralize the stomach acidity. Thirty min-
utes following the administration of isotonic solution, the
mice were orally intubated using a feeding needle and
given 1 3 106 PFU live HSV-1, 1 3 106 or 1 3 107 PFU of
uv HSV (titrated prior to inactivation), 1 3 107 PFU of
d120, d120 IFNg, or d120 IL4, or PBS alone as negative
control. Some groups of mice received a second dose 10
days later.
Vaginal challenge
In order to synchronize the estrous cycle of the mice at
the progesterone dominated stage, BALB/c female mice
were treated with progesterone, as previously described
by Parr et al. (1994). Briefly, BALB/c mice were injected sc
with 2 mg/mouse of Depo Provera (DP) (Upjohn Co.,
Kalamazoo, MI) 15 days after the last intragastric HSV-1
administration. Five days after the injection of DP, the
mice were challenged with 5 3 105 PFU of HSV-1 McK-
rae in 20 ml of PBS. These mice were examined for
vaginal inflammation, neurological illness, and death.
The severity of genital inflammation was scored as fol-
lows: 0, no vaginitis; 1, miled swelling or redness; 2,
moderate swelling; 3, severe genital maceration; 4, pa-
ralysis; and 5, death.
Zosterification challenge
Mice were challenged as described elsewhere (Man-
ickan et al., 1995). The left flank of mice was depilated 1
day before challenge. The mice were anesthetized using
metofane (Pitman-Moore, Mundelein, IL) and a total of 20
scarifications were made. To such scarifications 10 ml
containing 1 3 104 PFU of HSV-17 was added and gently
massaged. Animals were inspected daily for general
behavior changes, encephalitis, and mortality.
Collection of samples for antibody estimation
Serum was collected by retroorbital bleeding. Vaginal
washings were collected by introducing of 100 ml PBS
into the vaginal canals and then recovering (50 to 60 ml
per animal) with micropipet. The vaginal mucus was
subsequently removed by centrifugation and 20 ml of
each individual sample (six or eight mice per group)
were stored either pooled together or individually at
280°C. Fecal samples were weighed and suspended in
0.1% sodium azide in PBS at concentration 100 mg/ml.
Individual samples were stored at 280°C until used.
ELISA
ELISA plates (Dynatech Laboratories Inc., Chantilly,
VA) were coated with HSV Antigen (Advanced Biotech-
nology Inc., Columbia, MD) or goat-anti mouse IgG
(Southern Biotechnology Associates Inc., Birmingham,
AL) diluted in carbonate buffer (pH 9.6–9.8) and incu-
bated overnight at 4°C. The next day, the plates were
washed with PBS containing 0.05% Tween 20 (PBST), pH
7.4, and blocked for 1 h at 37°C with 200 ml/well PBST
containing 3% dehydrated milk. After washing, a known
concentration (100 ng/ml) of the standards IgG, IgG1, or
IgG2a (PharMingen, San Diego, CA) was added in trip-
licate to the anti-IgG coated wells and serially diluted.
Serum, fecal, and vaginal wash samples were added to
the HSV coated wells and were subsequently twofold
diluted in the ELISA plate. Samples from naive animals
were used as negative control. After 2 h incubation at
37°C the plates were washed and goat anti-mouse IgG,
IgG1, or IgG2a heavy chain specific antibody conjugated
to horseradish peroxidase (Southern Biotechnology As-
sociates) was added. After incubation for 1 h at 37°C and
subsequent washing, the substrate 2,2-azino-bis 3-ethil-
benz-thiasoline-6-sulfonic acid (ABTS) was added to the
wells for color development. The reaction was stopped
by adding 50 ml of 1.5% potassium fluoride (Sigma). The
plates were read at 405 nm with ELISA reader Model
EL310 (Autoreader BIO-TEK Instruments). The concentra-
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tion of antibodies was determined as described earlier
(Manickan et al., 1995).
Cytokine enzyme-linked immunospot (ELISPOT) assay
The ELISPOT assay was performed as described
previously (Kuklin et al., 1997). Briefly, nitrocellulose
plates (multiscreen-HA filtration plates, Millipore,
Bradford, MA) were coated with 2 mg/ml of monoclonal
anti-cytokine antibody diluted in sterile PBS at 4°C
overnight. Coating antibodies were purchased from
PharMigen (18191D, 18151D, 18111S for IL4, IL5, and
IFNg respectively). On day 2 the nitrocellulose plates
were washed three times with sterile PBS and blocked
with 100 ml/well of DMEM 10% FBS. The mesenteric
lymph node (MLN), spleen or PP cells were resus-
pended in DMEM 10% FBS and added to the ELISPOT
plates at serial dilutions of 1 3 106, 5 3 105 2 3 105,
1 3 105, and 5 3 104 cells/well. As a positive control,
cells were stimulated with ConA using 5 mg of ConA/
106 cells/ml in DMEM 10% FBS medium. The plates
were incubated in a vibration free incubator at 37°C
and 5% CO2 for 48 h. After incubation, the plates were
washed thrice with PBS and again three times with
PBST. Subsequently, 100 ml/well (1:1000 dilution) of
biotin conjugated monoclonal anti-cytokine antibody
(18042D, 18052D, 18112D for IL4, IL5, and IFNg, re-
spectively) diluted in PBST containing 1% FBS (PB-
STFB) was added. After incubation for 1 h at 37°C
plates were washed and alkaline phosphatase conju-
gated streptavidin (Jackson Immuno Research Labo-
ratories Inc., West Grove, PA) was added. Plates were
incubated for 1 h at 37°C, washed, and then substrate
(nitro blue tetrasolium (NBT), 5-bromo-4-chloro-3-indu-
lil phosphate (BICIP) was added for color develop-
ment. The spots were counted using a dissecting
microscope. In vitro HSV restimulation was done as
described before (Kuklin et al., 1997). Spleen or PP
cells were aseptically removed from the enterically
immunized animals. These cells were used as effec-
tors. Enriched dendritic cell (DC) populations were
used as stimulators. DCs were obtained as described
by Nair et al. (1995). The stimulators were pulsed for
3 h with uv HSV multiplicity of infection of 5 (virus
titrated prior to inactivation) and were added to re-
sponder to stimulator ratio of 50:1, 25:1, 12.5:1, and
6.25:1 into the precoated with anti-cytokine antibodies
ELISPOT plates. Plates were incubated for 3 days in a
vibration free incubator and the spots were developed
as described above.
ELISA for cytokine detection
Spleen cells from immunized animals were made into
single cell suspension in DMEM 10% FBS medium. One
milliliter on such suspensions containing 5 3 106 cells
was stimulated in vitro with multiplicity of infection
(m.o.i.) of UV-inactivated HSV-1 (KOS strain) (virus was
titrated prior to inactivation). Same amount of cells were
treated as unstimulated or ConA-stimulated (5 mg/5 3
106 cells/ml) in 12-well culture plates. Plates were incu-
bated at 37°C for 72 h. The supernatant was collected
and stored at 220°C until use. These supernatants were
screened for the presence of cytokines, namely IFNg,
IL5, and IL10 by ELISA as described previously (Manic-
kan et al., 1995). Briefly, ELISA plates were coated with
purified anti-mouse IFNg, IL5, or IL10 (catalog Nos.
18111S, 180151D, 18191D, PharMingen) at concentration
2 mg/ml at 4°C overnight. Subsequently after washing
and blocking samples or recombinant cytokines used as
standards were added to the plates and incubated for 2 h
at 37°C. Finally biotinilated monoclonal anti-mouse IFNg,
IL5, or IL10 (catalog Nos. 18112D, 18062D, 18042D,
Pharmingen) was added and incubated for 1 h at 37°C.
After washing avidin peroxidase (Zymed, South San
Francisco, CA, catalog No. 43-4423, 1:2000 dilution) were
added. The color was developed as described above.
Antibody ELISPOT assay
The number of spleen or Iliac lymph node (ILN) cells
producing anti-HSV IgA antibodies was measured by
ELISPOT as described by Milligan and Bernstein (1995).
Briefly, 96-well nitrocellulose plates (Millipore) were
coated with HSV antigen (Advanced Biotechnology) by
overnight incubation at 4°C. After blocking with DMEM
10% FBS, the ILN cells were added in 100 ml and incu-
bated for 48 h at 37°C. The plates were then washed
with PBS and PBST and incubated with biotinilated goat
anti-mouse IgA diluted 1:1000 (Pharmingen) for 1 h at
37°C. After washing, alkaline phosphatase-conjugated
streptavidin (Jackson Immuno Research) was added at
1:1000 dilution and incubated at 37°C for 1 h. Subse-
quently, the spots were developed as described above.
Construction of rHSV
The rHSV were constructed as described before
(Gage, 1992). Briefly, ICP4 mutant IFNg/HCMV-lacZ d120
was generated via Cre–lox recombination of a plasmid
which contained the ICP4 promoter driving the murine
IFNg or IL-4, an HCMV-b-galactosidase expression cas-
sette, and a lox recombination site into thymidine kinase
locus of d120. D120 is a herpes simplex type of virus KOS
strain containing a deletion in both copies of the imme-
diate–early ICP4 gene which renders its replication dif-
ficult unless grown on ICP4 complementing cell line (E5)
(Shepard and DeLuca, 1991). Recombinant virus was
screened via X-gal staining for b-galactosidase ex-
pression and purified via limiting dilution for three
rounds. Viral constructs were verified via Southern blot
analysis.
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In vitro cytokine production by IL4 or IFNg producing
replication deficient HSV
Human kidney fibroblasts (N 5 293) (ATCC CRL 1573)
were infected with d120, d120 IFNg, or d120 IL4 with a
m.o.i. of 10. The supernatants were tested for IFNg or IL4
production by ELISA. The levels of IFNg in the superna-
tants at 24 h postinfection were between 3000 and 4500
pg/million cells, whereas the levels of IL4 were in the
range of 400 pg/per million cells. No murine IL4 or IFNg
was detected from the supernatants of 293 cells infected
with d120 control virus.
Virus titration
Vaginal washings were collected at different time
points after intravaginal challenge by pipeting 100 ml of
PBS into the vaginal cavity. The samples were stored at
280°C until used. Individual samples (50 ml each) were
further diluted, and viral titers were determined using
plaque assay on vero cell monolayer as described pre-
viously (Spear and Roizman, 1972).
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